Enacting Risk-Based Quality Management in Clinical Development: Leadership-Enabled Learning in Early-Stage Biopharma
This qualitative comparative case study of two early-stage biopharma startups reveals that effective Risk-Based Quality Management (RBQM) is a dynamic, learning-driven process shaped by leadership-enabled practices that foster collective sensemaking, adaptive coordination, and cross-boundary collaboration to navigate scientific uncertainty and resource constraints.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Clinical trials are the rigorous experiments that determine whether a new medicine is safe and effective for people. For decades, the standard way to ensure these trials are done correctly has been to check everything, everywhere, all the time. This approach treats every step of the process with the same level of intense scrutiny, like a security guard checking every single item in a suitcase, regardless of whether it is a toothbrush or a dangerous weapon. However, as medical research has become more complex and global, this one-size-fits-all method has become difficult to manage. In response, regulators and scientists have developed a new strategy called Risk-Based Quality Management. This approach asks teams to focus their energy on the parts of the trial that are most likely to go wrong or cause harm, rather than spreading their attention thin across every single detail. It is a smarter way to work, but it requires a different kind of thinking than simply following a checklist.
The challenge is that while the rules for this new approach exist on paper, it is not always clear how real people in real companies actually make it work. This is especially true for small, early-stage biopharma startups. These are young companies with very few employees, often relying heavily on outside experts to run their trials. They operate with limited money and face huge scientific uncertainties every day. A recent study sought to understand how these small teams actually put risk-based quality management into practice. The researchers wanted to know how leaders and their teams learn to spot dangers, make decisions when they do not have all the facts, and work together when the path forward is unclear.
To find the answers, the researchers conducted a deep dive into two small biopharma companies, one based in the United States and the other in China. They spoke with six people who were directly involved in running these clinical trials, conducting a total of 42 interviews with them over time. These were not just scientists, but leaders and functional experts in areas such as clinical operations, medical affairs, and portfolio management who had to make daily decisions about how to keep their trials safe and on track. The researchers listened carefully to how these people described their work, looking for patterns in how they handled uncertainty and risk. They were not just interested in what rules the companies followed, but in how the people actually thought and talked to each other when things got complicated.
The study found that for these small teams, managing risk was not about following a static set of instructions. Instead, it was a living, breathing process that changed as the trial progressed. The researchers identified three main ways these teams succeeded. The first was what they called grounded adaptability. This means the teams stayed flexible and ready to change their plans when new information arrived, but they did not throw away all structure. They kept enough rules in place to ensure safety, but they adjusted how strictly they enforced those rules based on what they knew at the time. If a risk seemed small, they did not waste time on heavy paperwork. If a risk looked serious, they immediately added more checks. This allowed them to move fast without losing control.
The second key finding was the ability to calibrate the unknown. In early-stage drug development, teams often have to make important decisions without having all the data they would ideally like. They cannot wait for perfect information because time is critical. The study showed that these teams learned to judge how much uncertainty was acceptable. They would gather the information they had, discuss what was missing, and decide together whether to proceed. This was not a solitary decision made by a single boss. Instead, it was a group effort where doctors, scientists, and operations staff shared their different perspectives to spot blind spots. They learned to recognize weak signals—small hints or questions that something might be wrong—long before those hints turned into major problems.
The third element was symbiotic learning. This describes how knowledge flowed between the small company and the many outside partners they worked with, such as the hospitals running the trials and the companies hired to manage the data. The researchers found that these teams did not treat outside partners as just vendors to be monitored. Instead, they treated them as sources of vital information. When a partner raised a concern or shared an observation, the team listened and integrated that new knowledge into their own understanding of the risks. This constant exchange meant that learning happened all the time, everywhere, rather than being a separate task done once a year. The team learned from the partners, and the partners learned from the team, creating a shared understanding of how to keep the trial safe.
The study suggests that for risk-based quality management to work, it cannot just be a system of software or written procedures. It depends heavily on the people running the show and how they lead. The leaders in these successful teams created an environment where it was safe to ask questions and admit when things were uncertain. They encouraged open conversation where different viewpoints were welcomed, not silenced. This allowed the teams to catch risks early and solve problems together. The research indicates that when leaders foster this kind of open, learning-focused culture, the team becomes much better at spotting dangers and adapting to changes.
Ultimately, this research shows that managing risk in clinical trials is a social process as much as a technical one. It is about how people talk, listen, and learn from each other in the face of uncertainty. For small biopharma companies, which often lack the massive resources of big pharmaceutical corporations, this human element is their greatest strength. By building a culture where everyone is alert to risks and willing to share what they know, these teams can navigate the complex and dangerous waters of drug development. The study concludes that the most effective way to ensure the quality of a clinical trial is not just to build a better system, but to build a team that can think, learn, and adapt together.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.